Diet, metabolic disease and cancers in mouse models Joe Nadeau Chair, Department of Genetics Case Western Reserve University

Slides:



Advertisements
Similar presentations
DrMohammadSadrkabir Editor:. FREQUENCY OF ELEVATED HEPATOCELLULAR CARCINOMA (HCC) BIOMARKERS IN PATIENTS WITH ADVANCED HEPATITIS C The American Journal.
Advertisements

Immune Activation/Inflammation and HIV Disease Prof. Georg Behrens Department for Clinical Immunology and Rheumatology Hannover Medical School Germany.
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer in the world and the third most common cause of cancer mortality.
General Pathology Review. Assumptions Studying pathology enables us to better treat people Normal people participate positively in the society Activity.
What exactly is it that we are responsible for knowing from this website? There are many different photos of many different specific types of tumors...which.
Figure S1. ID#1 Lipid Metabolism, Small Molecule Biochemistry, Drug Metabolism.
 Primary liver cancer is the fifth most common cancer in the world and the third most common cause of cancer mortality  Hepatocellular carcinomas (HCCs)
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
NASH and nonalcoholic liver disease
Ontario College of Family Physicians 51 st Annual Scientific Assembly Barry Lumb Fatty Liver Disease.
Non Alcoholic Fatty Liver dis.
 Fatty liver disease can range from fatty liver alone (steatosis) to fatty liver associated with inflammation (steatohepatitis). This condition can occur.
Role of PXR Signaling in Mediating the Cardioprotective Effects of  -3 Fatty Acids Saraswathi Viswanathan, Ph.D. Assistant Professor Department of Internal.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Epidemiology of the Metabolic Syndrome in the USA Incidence ? Prevalence Distribution Control ? Incidence ? Prevalence Distribution Control ? Epidemiology.
THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.
Unit 5 – Public Health Chronic Diseases
Faculty of allied medical sciences
Diseases of the Pancreas November 19, 2007 NCDD Meeting Chair: Jane Holt Vice Chair: P. Jay Pasricha, MD.
1 MicroRNA Silencing of Tumor Suppressor DLC-1 Promotes Efficient Hepatitis C Virus Replication in Primary Human Hepatocytes 指導老師:鄭伯智老師、林宏榮老師 學生:林怡君 (N99H0005)
Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis Fazal Shirazi, PhD.
Non-alcoholic Fatty Liver Disease
LIVER CIRRHOSIS. Liver cirrhosis  Define Cirrhosis.  Recognize the types of cirrhosis.  Recognize the major causes and the pathogenetic mechanisms.
Hepatobiliary system Integrated practical
Liver Seminar for Health Plan Case Managers September 23, 2008 October 2, 2008.
Source: International Chair on Cardiometabolic Risk Metabolic Syndrome and Adipose Tissue Yuji Matsuzawa, MD, PhD Director.
Alcoholic liver disease
Jun Yu,1,2 Joseph Jao-Yiu Sung,1,2 Henry Lik-Yuen Chan1,2
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Jerrold J. Heindel PhD Acting Chief Cellular Organ and Systems Pathobiology Branch National Institute of Environmental Health Sciences National Institutes.
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:
ALCOHOLIC LIVER DISEASE. Alcohol is one of the most common causes of chronic liver disease worldwide,In the UK, a unit of alcohol contains 8 g of ethanol.
Pasi Erkkilä and Akseli Koskela
What Is the Disease of Obesity?
Patterns of Hepatic Injury
Chapter 11 Diet and Health
Hierarchical clustering of DEGs in Shp−/− mice, chronic hepatitis C cirrhosis, and NASH. A: unsupervised hierarchical clustering of genes common to the.
BY: Asmaa Alastal. wafaa hanouna. Salma abu taha. .Sara shaban
Fatty liver. In some cases, the fatty change seen in alcoholics will involve the entire liver (i.e., diffuse fatty liver). Fatty liver can also occur with.
Guidelines for the diagnosis and management of Nonalcoholic Fatty Liver Disease (NAFLD): Update in 2012 Sameh M Fakhry MD, Msc, PhD Consultant of Gastroenterology,
Chapter 10 Diet and Health
More Than Meets the Eye: Identifying Who Is at Risk for NASH
The New England Journal of Medicine (378;12) March 22, 2018
Volume 16, Issue 3, Pages (July 2016)
Nat. Rev. Nephrol. doi: /nrneph
Nutrigenomics KNH 413.
Genetics and epigenetics of NAFLD and NASH
Nat. Rev. Endocrinol. doi: /nrendo
T. Vescovo, G. Refolo, G. Vitagliano, G.M. Fimia, M. Piacentini 
Lymphotoxins: New Targets for Hepatocellular Carcinoma
Figure 1 Proposed algorithm for the management
Nutrigenomics KNH 413.
Nat. Rev. Nephrol. doi: /nrneph
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
Figure 2 Organ crosstalk in the pathophysiology
Figure 1 Simplified representation of the physiological
Example of algorithm for clinical assessment of patients at risk of non-alcoholic fatty liver disease Example of algorithm for clinical assessment.
Impact of metabolic risk factors on HCC
Genomic risk of hepatitis C-related hepatocellular carcinoma
Example of algorithm for clinical assessment of patients at risk of non-alcoholic fatty liver disease Example of algorithm for clinical assessment.
Mezale D*1, Strumfa I1, Balodis D1, Vanags A2, Rumba R2
Figure 1 NAFLD pathogenesis
Non-Infectious Diseases and Your Health
Should we undertake surveillance for HCC in patients with NAFLD ??
Mimic treatment induces eWAT inflammation and hepatic steatosis.
Whole-genome microarray analysis of gene expression in the livers of control mice and STAM mice subjected to NASH-derived hepatocarcinogenesis. Whole-genome.
Endoplasmic Reticulum Stress: At the Crossroads of Inflammation and Metabolism in Hepatocellular Carcinoma Development  Marion Maurel, Afshin Samali,
ATP III Guidelines Benefit Beyond LDL-Lowering:
Presentation transcript:

Diet, metabolic disease and cancers in mouse models Joe Nadeau Chair, Department of Genetics Case Western Reserve University

= + and Cancer risk and metabolic disease

Diet-induced obesity: Gene - diet interactions B6 on HFHS A/J on HFHS B6 on LFLS A/J on LFLS N ~ 25, Error Bars = 1 SD Normal diet HF: 58% kcal coconut oil LF: 11% kcal coconut oil Calorically balanced B6 - obese only with a HFHS diet A/J - lean regardless of diet

Long-term effects of high fat diet HCC 20 of 34 No NASH No HCC

B6-HF (5X) Non-alcoholic steatohepatitis (NASH) in B6 but not A/J mice -steatosis ( 40% of liver mass is lipid ) after 100 days on high fat, but not low fat diet - hepatitis ( inflammation ) - fibrosis - limited cirrhosis after 400 days A/J-HF (5X) (A/J LF) (B6 LF)

Diet-induced malignant transformation and hepatocellular carcinoma (HCC) Dysplastic nodule HCC Dysplastic nodules Cycles of cell damage, death and regeneration eventually lead to transformation, NASH - the ‘fertile soil’ in which transformation occurs

Hepatocellular carcinoma (HCC) 3 rd most common cause of cancer death worldwide Rapidly growing cause of cancer death in U.S. Risk factors: 1.Hepatitis B or C 2.Chronic alcohol use Remaining 30% of “unexplained” cases are frequently associated with obesity, diabetes, non- alcoholic steatohepatitis ~70% of cases (Ken Tanabe, MGH personal communication)

HCCs in humans and mice 1.Biochemistry 2.Histology 3.mRNA profiles 1.Molecular pathways ( Myc and NFkB ) 2.miRNA profiles ( X-linked cluster ) 3.Predicted mRNA targets of miRNAs Liver necrosis, cell death Liver steatosis Liver proliferation Hepatocellular carcinoma Cardiac degeneration, cell death Similar features in humans and mice

HCC No NASH No HCC No death Sudden death 35 days 135 days Diet-switch prevents HCC

Metabolic Syndrome, NASH, HCC On High Fat, High Sucrose Diet: B6 A/J Obesity Hypertension Insulin Resistance Cardiovascular Disease Risk X X X X  Genetics of disease Genetics of health J. Nadeau and E. Topol, Nat. Genet. 2006; Shao et al. PNAS; JHN et al, in prep X Hepatocellular carcinoma X Non-alcoholic steatohepatitis

HCC summary Diet-induced, rather than genetically- engineered or carcinogen-induced Similar pathology and molecular features Two pathways in one strain on the same diet Diet switch reverses outcome A similar diet modification may have important implications for prevention of HCCs in humans

HCC questions Genetic control of susceptibility chromosome substitution strains (Singer et al. Science 2004, Shao et al. PNAS 2008 ) Mechanisms of transformation engineered mutant genes and alternative fats Diet switch effects physiological mechanisms Interventions drugs and diets Biomarkers

David Buchner Annie Hill Eric Lander, Nate Berger, John Lambris, Mark Daly, Colleen Croniger, Aris Economides, Ken Tanabe, and Shankar Subramaniam Jon Giesinger Soha Yazbek Haifeng Shao Stephanie Doerner